Clinical Trials Logo

Clinical Trial Summary

In August 2020, West Nile Virus (WNV) was isolated from a live common whitethroat for the first time in The Netherlands. Follow-up sampling showed that the virus could also be detected in mosquitos from the same location during at least a whole month of sampling. On 15 October 2020, one case of West Nile virus infection has been reported in a man who was likely infected in the Utrecht region. This is the first time that a locally acquired human case of WNV infection has been reported in The Netherlands. Six additional cases have been identified, one of which from the region Arnhem. West Nile virus infection is a mosquito-borne zoonosis. The disease, which has spread across the Northern Hemisphere in the past three decades, is now found on an annual basis in many European countries where the centre of gravity lies in Southern-European countries. Recently, WNV was reported for the first time in Germany. The virus is transmitted among birds through the bite of infected mosquitoes and incidentally infects humans and other mammals, such as horses. Around 80% of human WNV infections are asymptomatic. The most common clinical presentation is West Nile fever but, older people and immunocompromised persons are at higher risk of developing neuro-invasive disorders (West Nile neuroinvasive disease). Currently, there are no prophylaxis or specific treatment against the disease in humans. In addition, Usutu virus (USUV) was detected in The Netherlands in 2016. USUV is another flavivirus, related to WNV, and also capable of infecting humans. Disease associated with USUV infection in humans appears to be milder and only limited number of cases have been identified. During their bird catching activities, bird ringers are intensively exposed to mosquito bites at the natural habitat of the birds and at the same time of the day when mosquitoes are particularly active. The aim of this study is therefore to determine the prevalence of WNV and USUV serum antibodies in bird ringers in The Netherlands.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05294003
Study type Observational
Source Leiden University Medical Center
Contact
Status Completed
Phase
Start date May 28, 2021
Completion date December 14, 2021

See also
  Status Clinical Trial Phase
Completed NCT00069316 - Omr-IgG-am(Trademark) for Treating Patients With or at High Risk for West Nile Virus Disease Phase 2
Completed NCT00097006 - Retrovirus Epidemiology Donor Study-II (REDS-II) N/A
Completed NCT00068055 - IVIG - West Nile Encephalitis: Safety and Efficacy Phase 1/Phase 2
Completed NCT00138463 - West Nile Virus Natural History N/A
Completed NCT00069303 - Natural History of West Nile Virus Infection N/A
Withdrawn NCT04371003 - Prospective Investigation of Oxidative Stress in West Nile Virus Infection
Completed NCT00387283 - Pharmacokinetic Study in Cerebral Spinal Fluid After a Single Dose of AVI-4020 Phase 1
Completed NCT02186626 - Evaluating the Safety and Immunogenicity of a Live Attenuated West Nile Virus Vaccine for West Nile Encephalitis in Adults 50 to 65 Years of Age Phase 1
Completed NCT00515385 - A Trial to Evaluate the Safety of a Single Intravenous Infusion of MGAWN1 in Healthy Adults Phase 1